Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2024 | 12 | 2.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 32 | 1.190 |
Why?
|
| Monocytes | 1 | 2023 | 27 | 0.850 |
Why?
|
| HIV Infections | 8 | 2024 | 4946 | 0.820 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 1 | 0.630 |
Why?
|
| Uterine Neoplasms | 1 | 2015 | 4 | 0.530 |
Why?
|
| Vaginal Neoplasms | 1 | 2015 | 3 | 0.530 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 11 | 0.520 |
Why?
|
| Prognosis | 5 | 2024 | 197 | 0.520 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 5 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2022 | 7 | 0.390 |
Why?
|
| Humans | 15 | 2024 | 14077 | 0.360 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2021 | 16 | 0.340 |
Why?
|
| Middle Aged | 8 | 2022 | 3425 | 0.330 |
Why?
|
| Retrospective Studies | 3 | 2024 | 767 | 0.310 |
Why?
|
| Aged | 5 | 2022 | 1650 | 0.290 |
Why?
|
| Adult | 9 | 2022 | 5664 | 0.290 |
Why?
|
| Rituximab | 2 | 2023 | 3 | 0.260 |
Why?
|
| Vincristine | 2 | 2023 | 5 | 0.260 |
Why?
|
| Prednisone | 2 | 2023 | 17 | 0.260 |
Why?
|
| Genes, myc | 2 | 2022 | 6 | 0.250 |
Why?
|
| Gene Rearrangement | 2 | 2022 | 15 | 0.250 |
Why?
|
| Female | 9 | 2022 | 8751 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2023 | 1 | 0.220 |
Why?
|
| Fluorescence | 1 | 2023 | 9 | 0.220 |
Why?
|
| Leukocyte Count | 1 | 2023 | 24 | 0.220 |
Why?
|
| Male | 8 | 2022 | 6489 | 0.220 |
Why?
|
| Color | 1 | 2022 | 2 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 5 | 0.200 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 104 | 0.200 |
Why?
|
| Hyperlipoproteinemia Type III | 1 | 2021 | 3 | 0.190 |
Why?
|
| Multiple Myeloma | 1 | 2021 | 12 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 6 | 0.190 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2021 | 9 | 0.190 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 26 | 0.180 |
Why?
|
| South Africa | 6 | 2023 | 7312 | 0.150 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 15 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 25 | 0.130 |
Why?
|
| Splenic Neoplasms | 1 | 2014 | 2 | 0.120 |
Why?
|
| Lymphoma, T-Cell | 1 | 2014 | 4 | 0.120 |
Why?
|
| Developing Countries | 1 | 2017 | 385 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 59 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 59 | 0.110 |
Why?
|
| Adolescent | 4 | 2019 | 2858 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 10 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 61 | 0.100 |
Why?
|
| Africa South of the Sahara | 1 | 2012 | 328 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2015 | 1410 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2010 | 6 | 0.090 |
Why?
|
| Ganciclovir | 1 | 2010 | 12 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2010 | 23 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 542 | 0.080 |
Why?
|
| HIV-1 | 2 | 2008 | 1239 | 0.070 |
Why?
|
| Sarcoma, Kaposi | 2 | 2008 | 52 | 0.070 |
Why?
|
| Neoplasms | 1 | 2008 | 141 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2024 | 9 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 5 | 0.060 |
Why?
|
| Young Adult | 3 | 2019 | 2357 | 0.060 |
Why?
|
| Ferritins | 1 | 2024 | 23 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2024 | 50 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2024 | 96 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2003 | 14 | 0.060 |
Why?
|
| Cytokines | 1 | 2024 | 107 | 0.060 |
Why?
|
| Apolipoprotein E2 | 1 | 2021 | 3 | 0.050 |
Why?
|
| Apolipoproteins E | 1 | 2021 | 4 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2003 | 266 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 10 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2021 | 11 | 0.050 |
Why?
|
| Triglycerides | 1 | 2021 | 40 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2021 | 23 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2021 | 95 | 0.050 |
Why?
|
| Africa | 1 | 2021 | 360 | 0.040 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2019 | 2 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 5 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 8 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 96 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 263 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 367 | 0.040 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 2 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 180 | 0.040 |
Why?
|
| Spleen | 1 | 2014 | 9 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 19 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 23 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2008 | 464 | 0.030 |
Why?
|
| Liver | 1 | 2014 | 74 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2017 | 530 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2010 | 19 | 0.020 |
Why?
|
| Neutropenia | 1 | 2010 | 9 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2010 | 24 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 113 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2010 | 38 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 153 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2010 | 107 | 0.020 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 4 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2008 | 11 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 867 | 0.020 |
Why?
|
| Time Factors | 1 | 2008 | 503 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 532 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2003 | 52 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 106 | 0.010 |
Why?
|
| Age Factors | 1 | 2003 | 364 | 0.010 |
Why?
|
| Prevalence | 1 | 2003 | 1149 | 0.010 |
Why?
|
| Risk Factors | 1 | 2003 | 1431 | 0.010 |
Why?
|